A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer - Wikidata - awgldk - TriplyDB

A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer

A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer

http://www.wikidata.org/entity/Q24626194

about

A perspective on anti-EGFR therapies targeting triple-negative breast cancer Targeted Therapies in Breast Cancer: Implications for Advanced Oncology Practice.HER Specific TKIs Exert Their Antineoplastic Effects on Breast Cancer Cell Lines through the Involvement of STAT5 and JNK.Clinical implications of molecular heterogeneity in triple negative breast cancer.Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC.Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET.Afatinib: first global approval.Optimal sequencing of anti-HER2 therapy throughout the continuum of HER2-positive breast cancer: evidence and clinical considerations.Emerging EGFR antagonists for breast cancer.Afatinib in the treatment of breast cancer.HER2-family signalling mechanisms, clinical implications and targeting in breast cancer.The Potential of panHER Inhibition in Cancer.Management of pulmonary toxicity associated with targeted anticancer therapies.Investigational ErbB-2 tyrosine kinase inhibitors for the treatment of breast cancer.New protein kinase inhibitors in breast cancer: afatinib and neratinib.Preclinical and clinical development of afatinib: a focus on breast cancer and squamous cell carcinoma of the head and neck.Breast cancer treatment-induced cardiotoxicity.Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges.A meta-analysis of biomarkers for the prognosis of triple-negative breast cancer patients.Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors.Metastatic and triple-negative breast cancer: challenges and treatment options Precision medicine based on tumorigenic signaling pathways for triple-negative breast cancer Therapeutic landscape in mutational triple negative breast cancer Cross-Database Analysis Reveals Sensitive Biomarkers for Combined Therapy for ERBB2+ Gastric Cancer

P2860

Q28069867-D94B2E54-3DB8-4F96-9B0E-0C41167490B7 Q35687574-21BA1CDB-E9A7-41F6-A555-F924A3EBC871 Q35886688-7B264BCF-A9A9-483C-8B4F-82E72A1F1AD7 Q36271396-4704651B-985B-4B9D-8ACD-018960ED9AB0 Q36673751-FB6821B6-F368-42B3-94E8-1E8D8F99CAA2 Q37141350-A10C1997-A510-46E6-AB11-76861F3D874F Q38132049-07CBE04C-970B-44F1-8A12-5AE524608852 Q38152742-627FCCBC-0430-47CE-902B-674487FAFD7F Q38211951-4A29E342-5BEA-4751-9DF5-424A5DA86D0F Q38215591-0E8293B1-4A81-4A79-BFCA-0EFD2EBD3C21 Q38301236-7CAA6BB1-00CD-4030-97E6-409A07DEC6F2 Q38352587-522A2F29-BB45-4D34-8CA0-76C62EBAEE73 Q38570532-58255308-7C74-4515-8AC2-A91B70C82168 Q38728508-9E9BDC00-5BC5-4734-8010-8DA9C921D36D Q39200319-9F1DE503-14FD-4D9F-B58D-57E27ACE34EF Q39297048-780EC5F1-A10F-47C5-B3E3-F6B5E858592E Q39428826-927A0C52-2778-45C4-A353-66C86AEC9EE4 Q49887925-EE5674A8-640D-45F9-B3AC-ABB77F31D15C Q51684386-720E9B06-9487-4E67-9A62-6215A2B6C9E7 Q54377793-BFEB0095-E83A-4D0F-9D4D-82B4219CB86B Q57105258-EF8E5C56-FF21-47E7-92E6-46CA9DE19E3F Q57105411-434C508A-87EC-43DD-B9D3-FF70C76E00AE Q57109569-C32D4F11-C2A3-4CB0-AF43-3826631A53AC Q58801774-F37C7A9B-DA76-457D-9F82-A0C72BD7A6E7

P2860

A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer

http://www.wikidata.org/entity/Q24626194

description

2012 nî lūn-bûn

@nan

2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

A phase II trial to assess eff ...... ative metastatic breast cancer

@ast

A phase II trial to assess eff ...... ative metastatic breast cancer

@en

A phase II trial to assess eff ...... ative metastatic breast cancer

@nl

type

label

A phase II trial to assess eff ...... ative metastatic breast cancer

@ast

A phase II trial to assess eff ...... ative metastatic breast cancer

@en

A phase II trial to assess eff ...... ative metastatic breast cancer

@nl

prefLabel

A phase II trial to assess eff ...... ative metastatic breast cancer

@ast

A phase II trial to assess eff ...... ative metastatic breast cancer

@en

A phase II trial to assess eff ...... ative metastatic breast cancer

@nl

P1433

Q24626194-3102DB50-494B-4160-8BAF-D2CAE6F5262D

P1476

Q24626194-C25FD19A-A2F7-4D74-95CF-BEF91147D383

P2093

Q24626194-0C154F4E-70C3-445D-9EA8-C8BC5FB71BD1

Q24626194-181AEF26-1678-4198-AA0F-4CF00F25D913

Q24626194-3860968A-27BD-46FD-AEB3-7A74B120F343

Q24626194-3D908D8D-F5FB-4540-9F09-A5B5B87D3D8E

Q24626194-44DF3755-F158-48BF-B353-86CC31D14215

Q24626194-528A4BE5-57E5-4576-871A-4CD44EB1C17A

Q24626194-6A04514E-9F31-444B-A026-6CC56DF66458

Q24626194-6D5A252C-082C-4A70-BCD6-1777CD1A3858

Q24626194-825B3410-17E9-469D-A2BA-34030EFCBB95

Q24626194-9173370E-D35C-44F4-8C1A-0D8CB562E48F

P2860

Q24626194-02C11DCC-1D38-4126-9586-315B71ACBA2D

Q24626194-11A7C82E-67D2-48EF-8D6D-DC07EE721F34

Q24626194-124F6267-EEAB-4FAF-B781-C4B652D23502

Q24626194-1629F131-891E-4A5B-B8F3-B6C391C15883

Q24626194-1CEB1A4F-F37C-4149-9551-CCAEF13A19DC

Q24626194-2488627A-871C-463C-9C31-98AA6E008C14

Q24626194-34007881-BEF9-449B-BE57-DE6F6232B878

Q24626194-3F982A2D-343D-42D2-890C-9C138C4A458C

Q24626194-4221F02E-8D66-4143-A503-7822CF40B265

Q24626194-4ECBA701-96B7-4D59-80E9-77112B094D5F

P2888

Q24626194-60D51554-0004-4DEA-AFF6-1B19AD533AD5

P304

Q24626194-4CFA0191-B8B0-483C-96C9-491F57254D22

P31

Q24626194-216A7164-A17B-42A7-9025-86625D872223

P356

Q24626194-51C192F4-5471-4F7B-8856-AC2AE504E000

P407

Q24626194-2896C876-5B11-423A-B082-5265F1DD1761

P433

Q24626194-5394852C-AD48-4F85-9D05-A57B5B219689

P478

Q24626194-FFB4396A-52CC-47F0-BAB0-EC85FEA63894

P50

Q24626194-100D6AED-6B3F-455F-9022-E8C0D73E2826

Q24626194-1FA8DA96-4C53-4791-8E12-9AC4600F037F

Q24626194-676A2F08-27C3-4E62-A774-7A1188AB3F96

Q24626194-B8DBAF21-570D-4B86-99B3-F3B643BA8982

P577

Q24626194-39E573A8-792F-48EB-8C69-1B2D2B196D8B

P5875

Q24626194-B811746F-DD82-4295-BD13-7A2B93898B30

P6179

Q24626194-0D1E0781-7E7C-40A8-B511-B08F8FBAE6C9

P698

Q24626194-87997592-8B65-46E2-9CDD-3BEEBFF36F37

P921

Q24626194-1848F5B0-4308-48F3-BF8B-ABE156F99668

Q24626194-99DAEF70-0C83-4290-A7E3-C9915C95343D

P932

Q24626194-A092EB80-7F00-4E98-AE6E-23EDBB389885

P356

S10549-012-2126-1

P1433

Breast Cancer Research and Treatment

P1476

A phase II trial to assess eff ...... ative metastatic breast cancer

@en

P2093

Ahmad Awada

http://www.w3.org/2001/XMLSchema#string

Frank Fleischer

http://www.w3.org/2001/XMLSchema#string

Jacques De Grève

http://www.w3.org/2001/XMLSchema#string

Jean Luc Canon

http://www.w3.org/2001/XMLSchema#string

Jochen Schütte

http://www.w3.org/2001/XMLSchema#string

Kurt Possinger

http://www.w3.org/2001/XMLSchema#string

Luc Dirix

http://www.w3.org/2001/XMLSchema#string

Marcus Schmidt

http://www.w3.org/2001/XMLSchema#string

Martin Schuler

http://www.w3.org/2001/XMLSchema#string

Martina Uttenreuther-Fischer

http://www.w3.org/2001/XMLSchema#string

P2860

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Molecular portraits of human breast tumours

Repeated observation of breast tumor subtypes in independent gene expression data sets

Iniparib plus chemotherapy in metastatic triple-negative breast cancer.

Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatme

Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.

Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer.

EGFR signaling in breast cancer: bad to the bone.

P2888

s10549-012-2126-1

P304

1149-59

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10549-012-2126-1

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

134

http://www.w3.org/2001/XMLSchema#string

P50

Peter A. Fasching

Matthias W. Beckmann

P577

2012-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

228324403

http://www.w3.org/2001/XMLSchema#string

P6179

1008433188

http://www.w3.org/2001/XMLSchema#string

P698

22763464

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

3409367

http://www.w3.org/2001/XMLSchema#string